234 related articles for article (PubMed ID: 15347088)
1. [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].
MMW Fortschr Med; 2004 Mar; 146(10):46. PubMed ID: 15347088
[No Abstract] [Full Text] [Related]
2. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
Thiebaud D
J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
[No Abstract] [Full Text] [Related]
3. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
[No Abstract] [Full Text] [Related]
4. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.
Riggs BL; Melton LJ
J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656
[No Abstract] [Full Text] [Related]
5. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
6. [Raloxifene hydrochloride].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
[No Abstract] [Full Text] [Related]
7. Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?
Hathirat S; Evans MF
Can Fam Physician; 2001 Oct; 47():1982-4. PubMed ID: 11723592
[No Abstract] [Full Text] [Related]
8. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
9. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene remains an option.
MacIver DW
Can Fam Physician; 2002 Apr; 48():679; author reply 679-80. PubMed ID: 12046354
[No Abstract] [Full Text] [Related]
11. Fewer fractures with raloxifene.
Feinberg AW
Health News; 1999 Oct; 5(12):3. PubMed ID: 10536528
[No Abstract] [Full Text] [Related]
12. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
MMW Fortschr Med; 2003 May; 145(22):57. PubMed ID: 12866287
[No Abstract] [Full Text] [Related]
13. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
14. Raloxifene therapy in the reduction of fractures.
Cefalu CA
Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
[No Abstract] [Full Text] [Related]
15. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
Vignot E; Meunier PJ
Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
[TBL] [Abstract][Full Text] [Related]
16. [MORE study(raloxifene)].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():442-9. PubMed ID: 15035168
[No Abstract] [Full Text] [Related]
17. Reduction of vertebral fracture risk with raloxifene.
Bashore R
J Fam Pract; 1999 Nov; 48(11):911-2. PubMed ID: 10907630
[No Abstract] [Full Text] [Related]
18. [Evidence of raloxifene on postmenopausal osteoporosis].
Okano H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
[No Abstract] [Full Text] [Related]
19. Raloxifene. Not better than estrogen.
Can Fam Physician; 2000 Aug; 46():1592-6, 1599-603. PubMed ID: 10955178
[TBL] [Abstract][Full Text] [Related]
20. [Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases].
Sakai A; Nakamura T
Clin Calcium; 2010 Mar; 20(3):322-9. PubMed ID: 20190361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]